



**THE FOUNDATION
FOR SECURE
MARKETS**

#48348

Date: February 24, 2021

Subject: Sunesis Pharmaceuticals, Inc. – Reverse Split and
Name/Symbol/CUSIP Change
Option Symbol: SNSS
New Symbol: VIRX2
Date: 02/25/21

Sunesis Pharmaceuticals, Inc. (SNSS) has announced a 1-for- 3.5 reverse stock split and a name, symbol, and CUSIP change. As a result of the reverse stock split and underlying changes, each SNSS Common Share will be converted into the right to receive approximately 0.285714 (New) Viracta Therapeutics, Inc. (VIRX) Common Shares. The reverse stock split and underlying changes will become effective before the market open on February 25, 2021. Cash will be paid in lieu of fractional VIRX shares.

Contract Adjustment

Effective Date: February 25, 2021

Option Symbol: SNSS changes to VIRX2

Contract Multiplier: 1

Strike Divisor: 1

New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

New Deliverable Per Contract: 1) 28 (New) Viracta Therapeutics, Inc. (VIRX) Common Shares
2) Cash in lieu of approximately 0.5714 fractional VIRX Shares

CUSIP: VIRX (New): 92765F108

Pricing

Until the cash in lieu amount is determined, the underlying price for VIRX2 will be determined as follows:

$$\text{VIRX2} = 0.285714 (\text{VIRX})$$

Delayed Settlement

The VIRX component of the VIRX2 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the VIRX2 deliverable until the cash in lieu of

fractional VIRX Shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theoocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theoocc.com.